Results 131 to 140 of about 15,930 (153)

Palbociclib in Combination With Endocrine Therapy Versus Capecitabine in Hormonal Receptor-Positive, Human Epidermal Growth Factor 2-Negative, Aromatase Inhibitor-Resistant Metastatic Breast Cancer: A Phase III Randomised Controlled Trial—PEARL☆

Annals of Oncology, 2021
Serafin Morales, Miguel Martin, Gil Miguel   +2 more
exaly  

Letrozole and Palbociclib Versus Chemotherapy as Neoadjuvant Therapy of High-Risk Luminal Breast Cancer

Annals of Oncology, 2018
Paul Cottu, David Gentien, Jean-Sébastien Frénel   +2 more
exaly  

Palbociclib as Single Agent or in Combination With the Endocrine Therapy Received Before Disease Progression for Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer: TREnd Trial

Annals of Oncology, 2018
Antonio Bernardo, Luca Malorni, Chiara Biagioni   +2 more
exaly  

Palbociclib: A First-in-Class CDK4/CDK6 Inhibitor for the Treatment of Hormone-Receptor Positive Advanced Breast Cancer

Journal of Hematology and Oncology, 2015
Janice Lu
exaly  

Palbociclib

Reactions Weekly, 2015
openaire   +1 more source

Clinical Considerations of the Role of Palbociclib in the Management of Advanced Breast Cancer Patients With and Without Visceral Metastases

Annals of Oncology, 2018
Miguel Martin, C Huang Bartlett, J Ettl
exaly  

Impact of Palbociclib Plus Letrozole on Patient-Reported Health-Related Quality of Life: Results From the PALOMA-2 Trial

Annals of Oncology, 2018
Hope Rugo, Miguel Martin, J Ettl
exaly  

A Phase II Feasibility Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor-Positive Invasive Breast Carcinoma

Annals of Oncology, 2019
W T Barry, C Huang Bartlett, S E Come
exaly  

Cost-Effectiveness of Palbociclib in Hormone Receptor-Positive Advanced Breast Cancer

Annals of Oncology, 2017
Sara M Tolaney, Hiroaki Mamiya, M Najafzadeh   +2 more
exaly  

Quality of Life With Palbociclib Plus Fulvestrant in Previously Treated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Patient-Reported Outcomes From the PALOMA-3 Trial

Annals of Oncology, 2016
Fabrice André, H Bhattacharyya, N Harbeck   +2 more
exaly